Back to Results
First PageMeta Content
Radiation therapy / Medicine / Angiology / Vascular endothelial growth factor


  Three-­‐year  Data  from  Oraya  Therapeutics’  INTREPID  Study  Continue  to  Show   Favorable  Safety  Profile  of  Non-­‐invasive  Wet  AMD  Therapy  
Add to Reading List

Document Date: 2014-09-25 19:26:33

Open Document

File Size: 83,25 KB

Share Result on Facebook

City

Sheffield / LONDON / NEWARK / /

Company

Domain Associates / Science Partners / Hallamshire Trust / AMD / Health Ventures / Therapeutics Inc. / /

Continent

Europe / /

Country

Switzerland / Germany / United States / United Kingdom / /

IndustryTerm

investigational device / energy / /

MedicalCondition

Ocular Cancers / macular degeneration / diseases / blindness / /

MedicalTreatment

innovative therapy / radiotherapy / radiation / /

Organization

NHS / /

Position

Professor of Ophthalmology / Professor / Oraya President and CEO / Consultant / /

Product

Oraya Therapy / VEGF injections / /

ProvinceOrState

California / /

Technology

radiation / laser / /

URL

www.orayainc.com / /

SocialTag